| Literature DB >> 33545689 |
Edward Schaeffer1, Sandy Srinivas2, Emmanuel S Antonarakis3, Andrew J Armstrong4, Justin E Bekelman5, Heather Cheng6, Anthony Victor D'Amico7, Brian J Davis8, Neil Desai9, Tanya Dorff10, James A Eastham11, Thomas A Farrington12, Xin Gao7, Eric Mark Horwitz13, Joseph E Ippolito14, Michael R Kuettel15, Joshua M Lang16, Rana McKay17, Jesse McKenney18, George Netto19, David F Penson20, Julio M Pow-Sang21, Robert Reiter22, Sylvia Richey23, Mack Roach Iii24, Stan Rosenfeld25, Ahmad Shabsigh26, Daniel E Spratt27, Benjamin A Teply28, Jonathan Tward29, Dorothy A Shead30, Deborah A Freedman-Cass30.
Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.Entities:
Year: 2021 PMID： 33545689 DOI： 10.6004/jnccn.2021.0008
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908